J
J. R. Infante
Researcher at Sarah Cannon Research Institute
Publications - 126
Citations - 4689
J. R. Infante is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Tolerability & Pharmacodynamics. The author has an hindex of 24, co-authored 126 publications receiving 4231 citations.
Papers
More filters
Journal ArticleDOI
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty,J. R. Infante,Adil Daud,Rene Gonzalez,Richard F. Kefford,Jeffrey A. Sosman,Omid Hamid,Lynn M. Schuchter,Jonathan Cebon,Nageatte Ibrahim,Ragini Kudchadkar,Howard A. Burris,Gerald S. Falchook,Alain Algazi,Karl D. Lewis,Georgina V. Long,Igor Puzanov,Peter F. Lebowitz,Ajay Singh,Shonda M Little,Peng Sun,Alicia Allred,Daniele Ouellet,Kevin B. Kim,Kiran Patel,Jeffrey S. Weber +25 more
TL;DR: Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
Journal ArticleDOI
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
J. R. Infante,Leslie A. Fecher,Sujatha Nallapareddy,Michael S. Gordon,Keith T. Flaherty,Donna S. Cox,Douglas J Demarini,Shannon R. Morris,H. A. Burris,Wells A. Messersmith +9 more
TL;DR: The objectives of this study are to define the maximum tolerated dose (MTD), and to evaluate the pharmacokinetics, pharmacodynamics, and response rate of GSK1120212 in advanced solid tumors and lymphoma.
Journal ArticleDOI
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
J. R. Infante,Gerald Steven Falchook,D. P. Lawrence,Jeffrey S. Weber,Richard F. Kefford,Johanna C. Bendell,R. Kurzrock,Geoffrey I. Shapiro,Ragini Kudchadkar,Georgina V. Long,H. A. Burris,K. B. Kim,Arthur Clements,Sheng-Bin Peng,B. Yi,Alicia Allred,Daniele Ouellet,Kiran Patel,Peter F. Lebowitz,Keith T. Flaherty +19 more
TL;DR: GSK212 at 2 mg QD combines safely with GSK436 150 mg BID, no SCC thus far and decreased frequency of rash compared to previous trials of single agent GSK 436 and GSK212, respectively.
Journal ArticleDOI
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
H. A. Burris,Jordi Rodon,Sunil Sharma,Roy S. Herbst,J. Tabernero,J. R. Infante,Antonio P. Silva,David Demanse,Wolfgang Hackl,J. Baselga +9 more
TL;DR: This phase I, multicenter, open-label, single-agent, dose-escalation, study was conducted in pts with histologically confirmed, advanced, unresectable solid tumors and anti-tumor activity of BEZ235 was assessed by CT and PET.
Journal ArticleDOI
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
Anthony W. Tolcher,Johanna C. Bendell,Kyri Papadopoulos,H. A. Burris,Amita Patnaik,Suzanne F. Jones,Drew W. Rasco,Donna S. Cox,Michael Durante,K.M. Bellew,Joohyun Jennifer Park,N.T. Le,J. R. Infante +12 more
TL;DR: This study was unable to identify a recommended phase II dose and schedule of trametinib in combination with everolimus that provided an acceptable tolerability and adequate drug exposure.